January 24, 2020 / 8:04 PM / 5 months ago

IFR US ECM WEEKLY WRAP-UP

NEW YORK, Jan 24 (IFR) -

WEEKLY TOTAL $4.58bn – IPO $800m – ABB/BLOCK $782m – FOLLOW-ON $2.45bn – CB $550m TUESDAY

Adaptimmune Therapeutics (UK, biotech) – $84m ABB. 21m shares (100% prim) at $4.00 versus $4.14 last sale. COWN. Upsized from $75m.

Ellington Financial (US, mortgage REIT) – $84.1m ABB. 4.6m shares (100% prim) at $18.29 fixed price versus $18.86 last sale. MS, CS, BOFA, UBS, KBW. Upsized from 4.2m shares. WEDNESDAY

Ares Commercial Real Estate (US, mortgage REIT) – $64.4m Block. 4m shares (100% prim) at $16.09 versus marketing at $16.09-$16.38 and $16.54 last sale. WF, CITI, MS.

Autolus Therapeutics (UK, biotech) – $79.8m ABB. 7.3m ADSs (100% prim) at $11.00 versus $11.00-$11.50 marketing and $12.47 last sale. JPM, JEFF, WMB.

Blueprint Medicines (US, biotech) – $325m F0. 4.7m shares (100% prim) at $69.00 versus $69.82 last sale and $79.74 at launch. GS, COWN.

Elanco Animal Health (US, animal health products) – $550m 3y mand cvt at 5%, up 20% versus fixed, 5% and 20% talk. GS, CITI, JPM.

Elanco Animal Health (US, animal health products) – $726.1m FO. 22.7m shares at $32.00 versus $32.23 last sale and $30.62 at launch. GS, CITI, JPM. Upsized from 19.2m shares.

Hutchison China MediTech (Hong Kong, pharmaceuticals) – $110m FO. 4.4m shares (100% prim) at $25.00 versus $25.69 last sale and $29.51 launch. BOFA, GS, MS, DB, HSBC.

ImmunoGen (US, biotech) – $90.6m ABB. 21.3m shares (100% prim) at $4.25 versus $4.68 last sale. JEFF, WMB. Upsized from $75m.

Si-Bone (US, surgical implants) – $92.5m FO. 4.3m shares (58% prim/42% sec) at $21.50 versus $22.04 last sale and $21.91 launch. MS, BOFA.

Trillium Therapeutics (US, biotech) – $101.7m ABB. 37m shares (100% prim) at $2.75 versus $3.27 last sale. COWN. Offering includes 35.7m common shares and 1.25m convertible preferred equivalent. Upsized from $75m.

Xenon Pharmaceuticals (US, biotech) – $60m ABB. 3.8m shares (100% prim) at $16.00 versus $16.83 last sale. JEFF, STFL, GUGG. Upsized from $50m.

Zai Lab (China, biotech) – $285m FO. 6m ADSs (92% prim, 8% sec) at $47.50 versus $48.48 last sale and $52.14 at launch. JPM, CITI, GS, SVBL.

Zymeworks (Canada, biotech) – $279m FO. 6m shares (100% prim) at $46.50 versus $49.80 last sale and $47.72 at launch. JPM, CITI. Includes pre-funded warrants to purchase up to 1.1m shares. Upsized from $200m fixed.

THURSDAY

Adaptive Biotechnologies (US, biotech) – $212.0m FO. 8m shares (100% sec) at $26.50 versus $26.85 last sale and $26.80 launch. JPM, GS, BOFA.

Applied Therapeutics (US, biotech) – $124.7m FO. 2.7m shares (100% prim) at $45.50 versus $48.85 last sale and $48.35 at launch. GS, COWN, BARC, UBS. Upsized from 1.75m shares to 2.25m shares in an SEC filing on 1/22.

Gores Holdings IV (US, SPAC) – $400m IPO. 40m units (100% prim) at $10.00. Each unit comprises one share and one-fourth of a warrant. DB, MS. Nasdaq “GHIV”.

Innovative Industrial Properties (US, REIT) – $217.4m ABB. 3m shares (100% prim) at $73.25 versus $79.45 last sale. BTIG. Upsized from 2m shares.

Minerva (Brazil, meat processing) - R$1.24bn FO. 95m shares (84% prim, 16% sec) at R$13.00 versus R$14.40 at launch. BTG, JPM, BRAD, BBIN, ITAU.

SCVX Corp (US, SPAC) – $200m IPO. 20m units (100% prim) at $10.00. Each unit comprises one share and one-half of a warrant. CS. (Reporting by Robert Sherwood)

Nuestros Estándares:Los principios Thomson Reuters
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below